April 20, 2015: The Ovarian Cancer Dream Team has been chosen! The Dream Team will focus on “DNA Repair Therapies for Ovarian Cancer,” building on recent advances that have identified DNA repair as a common weakness in ovarian cancer. Researchers will also explore the prevention and early detection of ovarian cancer by developing a … Continued
(April 16, 2015) The Society of Gynecologic Oncology has published recommendations for prevention of ovarian cancer in Cancer. Strategies include oral contraceptive use and tubal sterilization, as well as genetic counseling and testing for women from high-risk families. Read the abstract in ACS Journals.
(April 15, 2015) Doctors have long recognized that women with mutations in two particular genes – BRCA1 and BRCA2 – have a higher risk of breast and ovarian cancer. Now they are starting to figure out which mutations are worse than others. They have even discovered that some of these mutations may reduce a woman’s … Continued
(April 14, 2015) The FDA granted breakthrough therapy designation to rucaparib as monotherapy for patients with advanced ovarian cancer. Rucaparib is an oral, small-molecule PARP inhibitor developed for the treatment of platinum-sensitive ovarian cancer, specifically in patients with tumors that have BRCA mutations and other DNA deficiencies commonly referred to as “BRCA-like.” An FDA-designated “breakthrough … Continued
We are now accepting letters of intent for all research grants. LOIs are due May 8, 2015. Click here for more information.
(April 2, 2015) According to a study published in the journal Oncogene, the tumor microenvironment can regulate tumor suppressor miRNA in ovarian cancer cells. The direct interaction of the ovarian cancer cells with mesothelial cells, which cover the surface of the omentum, caused methylation mediated decrease in the expression of miR-193b in the tumor cells. … Continued
(April 1, 2015) A study published in Cancer Epidemiology, Biomarkers and Prevention looks at ovarian cancer risk in the general population. In U.S. women, lifetime risk of ovarian cancer is 1.37%, but some women are at a substantially lower or higher ovarian cancer risk due to both genetic and lifestyle factors. Leigh Pierce, PhD and … Continued
(March 27, 2015) According to research published this week in the Journal of Clinical Oncology, intraperitoneal (IP) chemotherapy is associated with a long-term survival advantage in ovarian cancer. The advantage of IP over intravenous chemotherapy extends beyond 10 years, and IP therapy enhanced survival of those with gross residual disease. Survival improved with increasing number … Continued
(March 20, 2015) This excellent, accessible piece in Mosaic Magazine, “Decisions on a Knife-Edge,” explores the difficult choices high-risk women face when considering how to decrease their chances of developing ovarian cancer. Removing only the fallopian tubes will avoid forcing a woman into early menopause, which is an appealing option for many women. Yet it’s not … Continued
(March 10, 2015) An algorithm developed at MD Anderson Cancer Center in Houston has dramatically increased complete resection rates in advanced ovarian cancer, giving patients the best possible chance of survival. The work was funded in part by an OCRF research grant to Anil Sood, MD. The results are summarized in an article in Nature … Continued
(February 17, 2015) OCRF-funded researchers at The Wistar Institute have identified a new therapeutic target in clear cell ovarian cancer, paving the way for what could be the first effective targeted therapy of its kind for the disease. The findings were published online by the journal Nature Medicine. The research was made possible in part … Continued
(February 13, 2015) University of Chicago Medicine researchers, including OCRF grantee and Scientific Advisory Committee member Ernst Lengyel, MD, PhD, have built a model system that uses multiple cell types from patients to rapidly test compounds that could block the early steps in ovarian cancer metastasis. Their three-dimensional cell-culture system, adapted for high-throughput screening, has … Continued
Get email updates about research news, action alerts, and ways to join the fight.
